Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 7Cetuximab 5selpercatinib 3cemiplimab 3Trastuzumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Erlotinib Hydrochloride 3Bortezomib 3sargramostim 2motexafin gadolinium 2entinostat 2Specimen Handling 2Radiotherapy 2Oxaliplatin 2Irinotecan 2Fluorodeoxyglucose F18 2Drug Therapy 2Docetaxel 2Biopsy 2ulixertinib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1tipifarnib 1tanespimycin 1spartalizumab 1serabelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Canagliflozin × Head & Neck × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡